Why is calling an ACE an ACE so controversial? Evaluating reference-based pricing in British Columbia

CMAJ. Canadian Medical Association Journal

Volumn 166, Issue 6, 2002, Pages 763-764

  Anis, Aslam ^a  

^a CENTRE FOR HEALTH EVALUATION AND OUTCOME SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; QUINAPRIL; RAMIPRIL;

BLOOD PRESSURE REGULATION; CANADA; DRUG COST; DRUG HALF LIFE; DRUG MARKETING; DRUG USE; HEALTH SERVICE; HUMAN; HYPERTENSION; LOWEST INCOME GROUP; NOTE; PRESCRIPTION;

EID: 0036206667     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (6)

1. Systematic review of antihypertensive therapies: Does the evidence assist in choosing a first-line drug?
2. Reference-based pricing of prescription drugs: Exploring the equivalence of antiogensin-converting-enzyme inhibitors
3. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization
4. Treatment of raised blood pressure in the population: The Canadian experience
5. A dog's breakfast: Prescription drug coverage varies widely across Canada